Is HAE a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Haemonetics (HAE) rests on Plasma, and the return of CSL: For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes, and the June 2026 quarter's roughly 8% organic plasma growth was the first clean read on that base. The bear case rests on customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. Analysts covering it publish targets from $115.00 to $165.00 against a $121.34 share price on November 16, 2026, so even the professionals disagree by 35% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
HAE key stats
At $121.34 on November 16, 2026, Haemonetics (HAE) has a market cap of $5.5B and a P/E of 53.7 on trailing earnings (19.5 on forward earnings). It next reports earnings around February 4, 2027 (estimated).
- Market cap
- $5.5B
- P/E (trailing)
- 53.7
- P/E (forward)
- 19.5
- EPS (trailing 12 months)
- $2.26
- Price to book
- 6.1
- Beta
- 0.59
- Next earnings
- around February 4, 2027 (estimated)
Market cap, P/E and yield are measured at the $121.34 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with Haemonetics (HAE)?
The last two weeks for Haemonetics, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- HAE closed at $121.34 on November 16, 2026, up 2.6% over the past five trading days (from $118.21).
- Haemonetics next reports quarterly results around February 4, 2027 (estimated).
- On November 5, 2026, Haemonetics filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov
- On November 5, 2026, Haemonetics filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
- On November 6, 2026, Citigroup raised its target to $149.00 from $123.00 (Buy).
- On November 6, 2026, Barrington Research raised its target to $145.00 from $140.00 (Outperform).
- On November 5, 2026, BTIG raised its target to $142.00 from $130.00 (Buy).
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
Haemonetics Corporation, based in Boston and listed on the NYSE, has sold blood-handling technology since 1971. Its largest business is plasma: the NexSys PCS apheresis machines, and the far more profitable single-use disposable kits that run on them, sit in the collection centers operated by companies like Grifols, Takeda's BioLife and Octapharma, which turn donated plasma into immunoglobulin and other plasma-derived therapies. A second business, grouped under the hospital umbrella, splits into Interventional Technologies (the VASCADE and VASCADE MVP vascular closure devices used after catheter procedures, plus the OpSens optical pressure sensing line and the Attune Medical esophageal cooling device) and Blood Management Technologies (TEG viscoelastic hemostasis analyzers, Cell Saver autotransfusion systems, and blood-tracking software). A third and shrinking business supplies whole-blood and apheresis collection to blood banks. The investment picture for the past several years was dominated by one contract. CSL Plasma, historically Haemonetics' single biggest plasma customer, chose not to renew and moved to a competing device, and the transitional supply that followed rolled off through fiscal 2025, leaving a revenue headwind in the roughly $70 million to $100 million range that suppressed reported growth into fiscal 2026. That comparison is now behind the company. In the quarter ended June 2026, the first of fiscal 2027, revenue was about $339 million, up roughly 6% on both a reported and organic basis, with plasma up about 8% organically and the hospital businesses up about 6%, and adjusted EPS of ~$1.14 beat the ~$1.08 consensus. Management raised the full-year outlook to roughly 5% to 8% reported growth. Then the story turned. On October 8, 2026 Haemonetics disclosed in an SEC filing that CSL Plasma expects to complete a rollout of Haemonetics devices and disposables by the end of 2027, with all of CSL's US collection centers expected to transition, though the filing noted that scope and timing could change. The shares rose ~16% that day. Haemonetics left fiscal 2027 guidance unchanged and said it would describe the expected impact of the CSL supply agreement on its fiscal second-quarter call, scheduled for November 5, 2026, where analysts expect ~$345 million of revenue and ~$1.29 of adjusted EPS. At ~$119.15 a share and about $5.4 billion of market value against roughly $1.35 billion of trailing revenue, the market now pays about four times sales, and the question has shifted from "how durable is what is left" to "how much revenue does CSL bring back, and how fast".
The bull case: what would have to be true for $165.00
The most optimistic published target on HAE is $165.00, +36.0% from the $121.34 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Plasma, and the return of CSL.
For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes, and the June 2026 quarter's roughly 8% organic plasma growth was the first clean read on that base. The October 2026 disclosure changes the shape of the next two years: CSL expects all of its US plasma centers to move to Haemonetics products, with the rollout complete by the end of 2027. If that happens on that timeline, plasma growth would be driven by a large customer returning rather than by yield gains alone. Underlying collection demand is tied to immunoglobulin therapy, which has grown steadily as diagnosis rates rise, and switching devices means requalifying an entire center network, which is why a returning customer tends to stay. The financial terms have not yet been disclosed; management plans to address them in November.
2. Yield software as a razor-blade lever.
Persona and the Persona PLUS rollout adjust how much plasma is drawn from each donor within the FDA nomogram, so a center collects more liters from the same donor pool and the same floor space. That matters because the customer's cost per liter falls while Haemonetics sells more disposables per visit. It is a way to grow revenue inside existing accounts rather than by winning new ones, which is the harder task in a market with few remaining buyers.
3. Interventional technologies after the ablation reset.
VASCADE MVP is used to close femoral access sites after cardiac ablation, and the rapid 2025 shift toward pulsed field ablation disrupted procedure mix and slowed that franchise. Management described the electrophysiology market as stabilizing in the June 2026 quarter, with interventional technologies returning to growth. The OpSens SavvyWire in structural heart and the Attune esophageal cooling device sit alongside it, and together these acquisitions represent roughly a billion dollars of capital that has yet to be fully validated by growth.
4. Hospital blood management as the steady leg.
TEG hemostasis analyzers and Cell Saver autotransfusion are installed-base businesses with recurring cartridge and bowl consumption, tied to surgical volumes rather than to any single therapy cycle. They grow in the mid single digits without much drama and fund the noisier parts of the portfolio. Blood management and vascular closure together drove the roughly 6% hospital growth reported for the June 2026 quarter.
The bear case: what would have to be true for $115.00
The most pessimistic published target is $115.00, -5.2% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks Haemonetics is worth if the risks below bite instead of the drivers above.
Customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. Pricing and ramp costs on that agreement are unknown until the November 5 call. Immunoglobulin demand has been reliable but is not guaranteed, and any move by a large customer toward in-house or competing collection hardware would repeat the problem. The interventional portfolio was assembled through three acquisitions in roughly two years, which leaves goodwill and intangibles on the balance sheet and about $1.17 billion of debt against them, and the pulsed field ablation transition has already demonstrated that a procedure-mix shift can cut into those products faster than the thesis assumed. The blood center business continues to decline as hospitals use less transfused blood, so mix has to keep improving just to hold consolidated growth flat. Tariffs, medical-device quality regulation and the pace of hospital capital budgets are the usual additional constraints on a company that manufactures physical disposables at scale.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HAE already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on HAE
10 analysts cover HAE, with an average target of $142.10 (+17.1% against $121.34) and a split of 9 buy, 2 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HAE forecast and price target page.
How is HAE valued?
Market cap, P/E and dividend yield at today's price are in the HAE key stats above. The business figures below come from Haemonetics's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$1.35B, up ~6% in the latest quarter
- Q1 FY2027 revenue (quarter ended June 2026): ~$339M, up ~6% organic; adj. EPS ~$1.14 vs ~$1.08 est.
- Net income (TTM): ~$96M; operating margin ~18%
- Price / TTM sales: ~4.0x
- FY2027 revenue growth guidance: ~5% to 8% reported (unchanged after CSL news)
As of October 2026: The multiple has re-rated from a little over three times sales in August to about four times, and from roughly the mid-teens to ~21x forward earnings, almost entirely on the CSL disclosure. Trailing GAAP EPS of ~$2.06 is held down by charges, including a loss in the March 2026 quarter, while analysts expect ~$5.31 of adjusted EPS for fiscal 2027 and ~$5.78 for fiscal 2028. The price now reflects a returning customer that has not yet shown up in revenue or guidance, which makes the November 5 call the next real test.
How do you decide if HAE is a buy?
Whether HAE is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HAE indirectly through an index or sector ETF before adding more.
What would change your mind on HAE
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Plasma, and the return of CSL stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the HAE stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HAE against your real portfolio and see your actual exposure before deciding.
Your questions about Haemonetics
Ask Walnut's AI anything about HAE and see how it fits what you own.
FAQ
Is HAE a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Plasma, and the return of CSL, with revenue (ttm) at ~$1.35B, up ~6% in the latest quarter. The bear case rests on customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. Analysts covering it are spread from $115.00 to $165.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell HAE?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $115.00, -5.2% from the $121.34 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for HAE?
+
Plasma, and the return of CSL. For the first time in several years, plasma revenue is being compared against a base that no longer contains the departed CSL volumes, and the June 2026 quarter's roughly 8% organic plasma growth was the first clean read on that base. The most optimistic analyst target on HAE is $165.00, +36.0% from the $121.34 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for HAE?
+
Customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change. Pricing and ramp costs on that agreement are unknown until the November 5 call. Immunoglobulin demand has been reliable but is not guaranteed, and any move by a large customer toward in-house or competing collection hardware would repeat the problem. The interventional portfolio was assembled through three acquisitions in roughly two years, which leaves goodwill and intangibles on the balance sheet and about $1.17 billion of debt against them, and the pulsed field ablation transition has already demonstrated that a procedure-mix shift can cut into those products faster than the thesis assumed. The blood center business continues to decline as hospitals use less transfused blood, so mix has to keep improving just to hold consolidated growth flat. Tariffs, medical-device quality regulation and the pace of hospital capital budgets are the usual additional constraints on a company that manufactures physical disposables at scale. The most pessimistic published target is $115.00, -5.2% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does Haemonetics do?
+
Plasma collection systems and disposables, plus hospital products including VASCADE vascular closure and TEG diagnostics.
What would have to change for HAE to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Plasma, and the return of CSL) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (customer concentration is the structural risk, and the CSL news cuts both ways: plasma collection in the United States is consolidated into a handful of buyers, the original CSL departure showed how much revenue a single non-renewal can remove, and the stock's ~139% one-year gain now assumes a CSL rollout whose scope and timing the company itself says could change) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does Haemonetics actually sell?
+
Machines and, more importantly, the single-use disposable kits that run on them. Plasma collection devices sit in donation centers, and hospital products include vascular closure devices, hemostasis analyzers and autotransfusion systems. The recurring disposable revenue, not the hardware, is where most of the margin comes from.
What was the CSL contract and why did it matter so much?
+
CSL Plasma was Haemonetics' largest plasma customer. It chose not to renew its supply agreement and moved to a competing collection device, with transitional supply running off through fiscal 2025. The revenue removed was in the roughly $70 million to $100 million range, which suppressed reported growth for two fiscal years. Fiscal 2027 is the first year comparing against a base without it. In October 2026 the relationship reversed: Haemonetics disclosed that CSL expects to transition all of its US plasma centers back to Haemonetics devices and disposables, completing the rollout by the end of 2027.
Is plasma growing again?
+
In the quarter ended June 2026, plasma revenue grew about 8% organically, and total company revenue reached about $339 million, up roughly 6%. That is the first clean quarter without CSL distorting the comparison. Whether mid to high single digits persists depends on immunoglobulin demand and on the Persona PLUS yield rollout at existing customers.
Walnut is informational, not investment advice, and gives no verdict on HAE. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.